Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis-Reference-Cited by-同舟云学术

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

Published:2024-02-22 Issue:5 Volume:67 Page:3571-3589
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Zhang Xiaojun¹^ORCID,Jiang Wen¹,Richter Jeremy M.¹^ORCID,Bates J. Alex¹,Reznik Samuel K.¹^ORCID,Stachura Sylwia¹,Rampulla Richard¹,Doddalingappa Dyamanna²,Ulaganathan Sankar²,Hua Ji¹,Bostwick Jeffrey S.¹,Sum Chi¹,Posy Shana¹,Malmstrom Sarah¹,Dickey Joyce¹,Harden David¹,Lawrence R. Michael¹,Guarino Victor R.¹,Schumacher William A.¹,Wong Pancras¹,Yang Jing¹,Gordon David A.¹,Wexler Ruth R.¹^ORCID,Priestley E. Scott¹

Affiliation:

1. Research & Early Development, Bristol Myers Squibb, 3551 Lawrenceville Road, Princeton, New Jersey 08540, United States

2. Department of Discovery Synthesis, Biocon Bristol Myers Squibb R&D Centre, Syngene International Ltd., Biocon Park, Plot No. 2 & 3, Bommasandra−Jigani Road, Bangalore 560099, India

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01986

Reference30 articles.

1. New directions for pharmacotherapy in the treatment of acute coronary syndrome

2. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome

3. Novel aspects of antiplatelet therapy in cardiovascular disease

4. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA

5. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protease activated receptor-4: ready to be part of the antithrombosis spectrum;Current Opinion in Hematology;2024-05-30